Swiss Biotech Stock News

OC Oerlikon stock comes into this earnings day on a tear, up about 36% over the past three months, which sets a high bar for any result. The headline this time is not about eye catching revenue growth; it is about margins. Operational EBITDA of CHF 156m in the first half with a 19.7% margin and a 300 basis point expansion has turned the spotlight onto profitability rather than top line noise. The question now is whether that margin story fully justifies the recent re rating or whether short...

Galenica just served up earnings that look stronger than the recent share price would suggest. The stock closed at CHF82.2 on 7 August, with the past month and quarter both in slightly negative territory. Yet underneath that soft chart sits a healthcare retailer and distributor that reported H1 2026 sales of CHF2.143b and an adjusted earnings before interest and taxes margin in its Products & Care arm that edged higher. For a company often viewed as a dependable Swiss healthcare utility, the...

Swisscom stock heads into this earnings reaction priced for caution rather than excitement. The share price is roughly flat over the past week and month, and it has slipped about 6% over the last quarter, even as the company trades on a relatively rich trailing P/E of 24.8x. The headline from this quarter is not revenue movement. It is the profit squeeze. Net margin on a trailing basis now sits at 8.9%, lower than 10.2% a year earlier, even as management leans on Italian synergies and Swiss...

Swiss Re stock closed at CHF138.50, capping a solid 90 day run that left holders already sitting on a double digit gain before these results hit the tape. The headline today is simple. The market is reacting to a reinsurer that has already booked US$2.8b in net income for the first half of 2026 and a 23% return on equity. For short term traders, the question is how much of that strength is already priced in. For long term investors, the focus shifts to what those earnings and margins say...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

EMS-CHEMIE HOLDING AG ( VTX:EMSN ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is commonly...

It's been a pretty great week for ams-OSRAM AG ( VTX:AMS ) shareholders, with its shares surging 12% to CHF17.61 in the...

Investors were underwhelmed by the solid earnings posted by Logitech International S.A. ( VTX:LOGN ) recently. We did...

Sandoz Group shareholders walked into this earnings day with a stock that had inched higher over the past week but gone essentially sideways over the past month. The market is still trying to decide whether a rich P/E of 57.2x belongs on a generics and biosimilars specialist or on a high growth story that just happens to sell off patent drugs. H1 2026 results gave that debate fresh fuel. Net sales reached about US$5.8b with a core earnings before interest, tax, depreciation and amortisation...

In recent weeks, the European market has shown resilience, with the STOXX Europe 600 Index reaching new highs driven by robust corporate earnings and a recovery in sentiment toward AI-related stocks. As investors navigate these dynamic conditions, dividend stocks present an appealing option for those seeking stable income streams and potential growth opportunities amidst economic fluctuations.

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting half year 2026 results on 24 July, with higher net interest income and net income than in the same period a year earlier. See our latest analysis for Vontobel Holding. At a share price of CHF85.90, Vontobel Holding has seen strong recent momentum, with a 30 day share price return of 11.85% and a year to date share price return of 30.15%. The 1 year total shareholder return of 50.68% and 3 year total shareholder...

Roche Holding (SWX:ROP) has seen fresh attention after the U.S. FDA granted 510(k) clearance for its cobas BV/CV molecular assay. This clearance expands the company’s diagnostics menu in vaginal and broader sexual health testing. See our latest analysis for Roche Holding. Alongside the new cobas BV/CV assay, Roche Holding’s share price is at CHF364.70, with a 30-day share price return of 9.92% and a 1-year total shareholder return of 51.19%, indicating that momentum has been building despite...

Avolta (SWX:AVOL) is in focus after its half year 2026 earnings update showed lower sales and revenue than a year earlier, alongside higher net income and earnings per share from continuing operations. See our latest analysis for Avolta. Avolta’s share price closed at CHF49.44 on 30 July, with a 90 day share price return of 9.72% and a year to date share price return of 5.69%. The 1 year total shareholder return of 19.55% and 3 year total shareholder return of 27.03% point to momentum that...

Partners Group Holding (SWX:PGHN) is drawing attention after an AI transformation program at portfolio company Foundation Risk Partners reportedly lifted EBITDA margin by 120 bps and shortened policy processing times. See our latest analysis for Partners Group Holding. Against this backdrop, Partners Group Holding’s recent AI driven value creation sits alongside a share price that has risen 3.4% over the past week and 5.8% over the past month. However, the share price remains down 30.4% year...

SGS (SWX:SGSN) drew fresh attention after releasing its half year 2026 results, reporting sales of CHF 3,683 million and net income of CHF 309 million, alongside slightly lower earnings per share than a year earlier. See our latest analysis for SGS. Since the July earnings release, SGS has seen momentum build, with a 12.05% 90 day share price return and a 23.20% 1 year total shareholder return at a latest share price of CHF 98.04. If the SGS update has you thinking about where else growth and...

VAT Group (SWX:VACN) drew fresh investor focus after issuing earnings guidance for the third quarter of 2026 and confirming its full year outlook, including expectations for higher sales and net income versus 2025. See our latest analysis for VAT Group. The latest guidance appears to have supported sentiment around VAT Group, with the share price at CHF626.4 after a 3.1% one day share price return and a 44.8% year to date share price return. At the same time, the 124.1% one year total...

Half-year earnings set the stage for Bucher Industries stock discussion Bucher Industries (SWX:BUCN) reported half year 2026 results with sales of CHF 1,471.4 million and net income of CHF 87.5 million, both below the prior year. This shift can matter for investors. See our latest analysis for Bucher Industries. The half year earnings update appears to sit against a weak share price backdrop for Bucher Industries, with the share price down 13.9% year to date and the 1 year total shareholder...

Holcim (SWX:HOLN) moved back into focus after its H1 2026 results on 31 July, with modest sales of CHF 7,925 million and stable earnings per share from continuing operations attracting close investor attention. See our latest analysis for Holcim. Following the H1 2026 announcement on 31 July, Holcim’s share price has eased recently, with a 30 day share price return of down 4.99% and year to date share price return of down 6.35%. Total shareholder return over five years is up 224.57%,...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

As you might know, Interroll Holding AG ( VTX:INRN ) recently reported its half-yearly numbers. Results overall were...

Shareholders will be ecstatic, with their stake up 28% over the past week following Clariant AG 's ( VTX:CLN ) latest...

Komax Holding AG ( VTX:KOMN ), is not the largest company out there, but it saw a significant share price rise of 39...

ams-OSRAM stock closed at CHF17.21 on 4 August after a choppy month that left the shares down about 14% over 30 days but still up roughly 37% over three months. The market has been wrestling with that volatility against an earnings print that put revenue at €805m for Q2 2026 and kept adjusted earnings before interest, tax, depreciation and amortisation close to the top of guidance. The real headline is not the quarterly loss. It is that core semiconductor revenue and fresh design wins point...